Navigation Links
Number of Patients Treated with an Antibiotic for MRSA Within U.S. Acute Care Hospitals Increased 8 Percent from 2006 to 2007
Date:6/25/2008

However, the Average Number of Days of Inpatient Therapy per Patient Treated with an Antibiotic for MRSA Decreased by 10 Percent, According to

New Data Released by Arlington Medical Resources

MALVERN, Penn., June 25 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that the number of patients treated with an antibiotic associated with a positive culture for MRSA within U.S. acute care hospitals has increased from 2006 to 2007 by 8 percent. However, the average number of days of inpatient therapy per patient treated with an antibiotic associated with a positive culture for MRSA decreased by 10 percent.

The newly released edition of The U.S. Hospital Antibiotic Market Guide finds that the most common infections among these patients with a positive culture for MRSA are:

-- Skin/skin structure infections (46 percent of patients)

-- Systemic infections (19 percent of patients)

-- Lower respiratory infections (19 percent of patients)

Why Pharmaceutical Companies Need this Information

The U.S. Hospital Antibiotic Market Guide allows pharmaceutical companies to quantify the clinical utilization of hospital antibiotics at a highly granular level in the United States. It is the most comprehensive data available to gain insights into clinical usage and prescriber dynamics of hospital antibiotics, including gram positive and gram negative agents.

"With a large pipeline of late-stage anti-MRSA products, biopharmaceutical companies are demanding accurate information on MRSA usage patterns and trends so they can understand the current market and how treatments will evolve with the launch of new anti-MRSA drugs," said Joyce Wedemeyer, product director at AMR. "The U.S. Hospital Antibiotic Market Guide allows marketing, new product planning, market research and marketing teams to understand how antibiotic products are used in terms of combination therapy, types of infections, treatment intent and setting, and the types of specialists who are prescribing."

About U.S. Hospital Antibiotic Market Guide

The U.S. Hospital Antibiotic Market Guide is a semiannual syndicated clinical audit of antibacterial use in U.S. acute care hospitals. The audit is based on antibacterial census data from 250 demographically representative hospitals, plus a detailed clinical review of 11,000 randomly selected inpatient records yielding 25,000 antibiotic drug courses each 6-month audit cycle. The Hospital Antibiotic Market Guide is also available for France, Germany, Italy, Spain and the United Kingdom.

About AMR

AMR (http://www.AMR-data.com) is a pharmaceutical market research firm serving the market intelligence needs of the pharmaceutical and diagnostic imaging industries since 1991. With offices in Malvern, PA and Brussels and affiliates in Tokyo, Seoul and Shanghai, AMR publishes syndicated audits for the United States, Italy, Germany, United Kingdom, France, Spain, China, Japan and Korea. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ASCO Results: Oncologists Rank Genentech Number One
2. Nikon Instruments Receives Record Number of Entries for Nikon Small World
3. Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada
4. Nanotubes grown straight in large numbers
5. BioSpace Career Fair in San Diego Draws Record Number of Bioscience Candidates
6. The neural basis of number sense in young infants
7. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
8. New Aptivus(R) (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients
9. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
10. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
11. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):